PT Kalbe Farma Unsponsored Indonesia ADR (PTKFY) Presyo at Balita

(IDR)	Set 2024	Y/Y na pagbabago
Kita	7.91T	7.16%
Gastos sa pagpapatakbo	2.29T	15.55%
Net na kita	573.28B	6.97%
Net profit margin	7.25	-0.14%
Kita sa bawat share	12.41	7.73%
EBITDA	874.81B	1.14%
Aktuwal na % ng binabayarang buwis	23.01%	—

Balance Sheet

Kabuuang asset

Kabuuang sagutin

(IDR)	Set 2024	Y/Y na pagbabago
Cash at mga panandaliang investment	4.32T	45.45%
Kabuuang asset	28.75T	5.78%
Kabuuang sagutin	4.84T	0.67%
Kabuuang equity	23.91T	—
Natitirang share	46.15B	—
Presyo para makapag-book	0.04	—
Return on assets	6.15%	—
Return on capital	7.16%	—

Cash Flow

Net change in cash

(IDR)	Set 2024	Y/Y na pagbabago
Net na kita	573.28B	6.97%
Cash mula sa mga operasyon	1.16T	22.56%
Cash mula sa pag-invest	-176.64B	33.78%
Cash mula sa financing	-421.11B	51.91%
Net change in cash	481.86B	1,978.42%
Malayang cash flow	752.00B	13.84%

Tungkol

PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. Wikipedia

Itinatag

Set 10, 1966

Website

kalbe.co.id

Mga Empleyado

12,924